

AgOTf-Catalyzed Tandem Reaction of *N'*-(2-Alkynylbenzylidene)-hydrazide with Alkyne

Zhiyuan Chen, Xiaodi Yang, and Jie Wu*

Department of Chemistry, Fudan University, 220 Handan Road, Shanghai 200433, China

jie_wu@fudan.edu.cn


Supporting Information

1. General experimental methods (S2)
2. General experimental procedure and characterization data. (S2-S9).
3. ¹H and ¹³C spectra of compound **3** (S10-S41).


General experimental methods:

All reactions were performed in reaction tubes under nitrogen atmosphere. Flash column chromatography was performed using silica gel (60-Å pore size, 32–63 μm, standard grade). Analytical thin-layer chromatography was performed using glass plates pre-coated with 0.25 mm 230–400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Thin layer chromatography plates were visualized by exposure to ultraviolet light. Organic solutions were concentrated on rotary evaporators at ~20 Torr (house vacuum) at 25–35°C. Commercial reagents and solvents were used as received. Nuclear magnetic resonance (NMR) spectra are recorded in parts per million from internal tetramethylsilane on the δ scale. *N'*-(2-Alkynylbenzylidene)hydrazide was synthesized according to the literature method (Anderson, P. N.; Sharp, J. T.; et al, J. Chem. Soc., Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), **1980**, (6), 1331-1334.)

General procedure for AgOTf-catalyzed tandem reaction of *N'*-(2-alkynylbenzylidene)hydrazide with alkyne:




A mixture of *N'*-(2-alkynylbenzylidene)hydrazide **1** (0.20 mmol) and AgOTf (10 mol %) in anhydrous DCE (0.5 mL) was heated at 70 °C for 3 hours. The mixture was then cooled to room temperature. A solution of DBU (0.6 mmol, 3.0 equiv) and alkyne **2** (0.3 mmol, 1.5 equiv) in CCl₄ (2.0 mL) was added subsequently. The mixture was stirred at room temperature overnight. After completion of the reaction as indicated by TLC, the solvent was evaporated. The residue was diluted with EtOAc (10 mL), washed with H₂O (10 mL), dried by anhydrous MgSO₄. Evaporation of the solvent followed by purification on silica gel provided the corresponding product **3**.




3a. 2,5-diphenylpyrazolo[5,1-a]isoquinoline.

Yield: 80%; ^1H NMR (400 MHz, CDCl_3): 7.05 (s, 1H), 7.32-7.35 (m, 1H), 7.38 (s, 1H), 7.41-7.44 (t, $J = 7.3$ Hz, 2H), 7.50-7.56 (m, 5H), 7.71-7.73 (m, 1H), 7.98-8.05 (m, 4H), 8.12-8.15 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 94.7, 112.5, 123.5, 123.9, 126.4, 127.2, 127.3, 127.9, 128.1, 128.6, 129.2, 129.3, 129.6, 133.4, 133.7, 138.4, 140.7, 152.2; HRMS calcd. for $\text{C}_{23}\text{H}_{16}\text{N}_2^+ [\text{M}+\text{H}]^+$: 321.1392, found 321.1383.




3b. 2-(4-methoxyphenyl)-5-phenylpyrazolo[5,1-a]isoquinoline.

Yield: 74%; ^1H NMR (400 MHz, CDCl_3): 3.85 (s, 3H), 6.96 (d, $J = 8.3$ Hz, 2H), 7.05 (s, 1H), 7.32 (s, 1H), 7.50-7.58 (m, 5H), 7.72-7.74 (m, 1H), 7.92-7.94 (m, 2H), 8.02-8.05 (m, 2H), 8.13-8.15 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 55.3, 94.2, 112.2, 113.9, 123.5, 123.8, 126.1, 127.1, 127.6, 127.9, 128.1, 129.2, 129.3, 129.6, 133.8, 138.3, 140.7, 152.1, 159.7; HRMS calcd. for $\text{C}_{24}\text{H}_{18}\text{N}_2\text{O}^+ [\text{M}+\text{H}]^+$: 351.1497, found 351.1497




3c. 2,5-bis(4-methoxyphenyl)pyrazolo[5,1-a]isoquinoline.

Yield: 70%; ^1H NMR (400 MHz, CDCl_3): 3.85 (s, 3H), 3.90 (s, 3H), 6.96-7.00 (m, 3H), 7.05-7.08 (m, 2H), 7.30 (s, 1H), 7.49-7.55 (m, 2H), 7.69-7.71 (m, 1H), 7.93-7.96 (m, 2H), 7.99-8.03 (m, 2H), 8.10-8.12 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 55.4, 55.5, 94.3, 111.5, 113.7, 114.1, 123.6, 123.7, 126.3, 127.0, 127.1, 127.8, 127.9, 129.5, 131.1, 138.2, 140.9, 152.1, 159.8, 160.4; HRMS calcd. for $\text{C}_{25}\text{H}_{20}\text{N}_2\text{O}_2^+$ $[\text{M}+\text{H}]^+$: 381.1603, found 381.1612.



3d. 5-butyl-2-phenylpyrazolo[5,1-a]isoquinoline.


Yield: 99%; ^1H NMR (400 MHz, CDCl_3): 1.02 (t, $J=7.3$ Hz, 3H), 1.50-1.53 (m, 2H), 1.89-1.93 (m, 2H), 3.21 (t, $J=7.3$ Hz, 2H), 6.78 (s, 1H), 7.29 (s, 1H), 7.34-7.38 (m, 1H), 7.44-7.50 (m, 4H), 7.62-7.64 (m, 1H), 8.04-8.08 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.9, 22.5, 28.9, 30.5, 94.5, 109.3, 123.4, 126.3, 126.4, 126.5, 127.6, 128.1, 128.7, 129.2, 133.6, 139.6, 140.0, 151.9; HRMS calcd. for $\text{C}_{21}\text{H}_{20}\text{N}_2^+$ $[\text{M}+\text{H}]^+$: 301.1705, found 301.1689.



3e. 5-butyl-2-(4-methoxyphenyl)pyrazolo[5,1-a]isoquinoline.


Yield: 94%; ^1H NMR (400 MHz, CDCl_3): 1.01 (t, $J=7.3$ Hz, 3H), 1.49-1.55 (m, 2H), 1.87-1.94 (m, 2H), 3.20 (t, $J=7.3$ Hz, 2H), 3.84 (s, 3H), 6.75 (s, 1H), 6.98 (d, $J=8.7$ Hz, 2H), 7.20 (s, 1H), 7.44-7.47 (m, 2H), 7.60-7.62 (m, 1H), 7.95-7.99 (d, $J=8.7$ Hz, 2H), 8.02-8.06 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.0, 22.6, 28.9, 30.5, 55.3,

94.0, 108.9, 114.0, 123.2, 123.3, 126.3, 126.4, 127.5, 129.2, 139.6, 140.0, 151.8, 159.6; HRMS calcd. for $C_{22}H_{22}N_2O^+$ $[M+H]^+$: 331.1810, found 331.1811.




3f. 2,5-dibutylpyrazolo[5,1-a]isoquinoline.

Yield: 75%; 1H NMR (400 MHz, $CDCl_3$): 0.93-1.02 (m, 6H), 1.41-1.59 (m, 4H), 1.72-1.81 (m, 2H), 1.82-1.91 (m, 2H), 2.89 (t, $J = 7.8$ Hz, 2H), 3.15 (t, $J = 7.8$ Hz, 2H), 6.73 (s, 1H), 6.82 (s, 1H), 7.44-7.46 (m, 2H), 7.61-7.63 (m, 1H), 8.00-8.02 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 13.9, 14.0, 22.5, 22.6, 28.5, 28.8, 30.4, 32.1, 96.1, 108.1, 123.2, 123.3, 126.1, 126.3, 127.4, 129.2, 139.3, 139.4, 154.9; HRMS calcd. for $C_{19}H_{24}N_2^+$ $[M+H]^+$: 281.2018, found 281.2018.




3g. 5-butyl-2-cyclopropylpyrazolo[5,1-a]isoquinoline.

Yield: 62%; 1H NMR (400 MHz, $CDCl_3$): 0.88-0.92 (m, 2H), 0.97-1.02 (t, $J = 7.4$ Hz, 3H), 1.03-1.06 (m, 2H), 1.47-1.58 (m, 2H), 1.84-1.94 (m, 2H), 2.19-2.22 (m, 1H), 3.14 (t, $J = 7.4$ Hz, 2H), 3.86 (s, 3H), 6.62 (s, 1H), 6.72 (s, 1H), 7.44-7.47 (m, 2H), 7.61-7.63 (m, 1H), 7.96-7.99 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 8.91, 9.70, 14.0, 22.5, 28.8, 30.4, 93.1, 108.1, 123.0, 123.3, 126.1, 126.3, 127.4, 129.2, 139.2, 139.5, 156.8; HRMS calcd. for $C_{18}H_{20}N_2^+$ $[M+H]^+$: 265.1705, found 265.1697.




3h. (5-butylpyrazolo[5,1-a]isoquinolin-2-yl)methanol.

Yield: 64%; ^1H NMR (400 MHz, CDCl_3): 0.99 (t, $J=7.3$ Hz, 3H), 1.44-1.54 (m, 2H), 1.81-1.88 (m, 2H), 2.69 (br, 1H), 3.12 (t, $J=7.3$ Hz, 2H), 4.96 (s, 2H), 6.78 (s, 1H), 6.99 (s, 1H), 7.46-7.52 (m, 2H), 7.63-7.65 (m, 1H), 8.00-8.03 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.0, 22.5, 28.8, 30.4, 59.5, 95.8, 109.2, 123.2, 123.4, 126.4, 126.5, 127.8, 129.1, 139.3, 139.7, 153.2; HRMS calcd. for $\text{C}_{16}\text{H}_{18}\text{N}_2\text{O}^+$ $[\text{M}+\text{H}]^+$: 255.1497, found 255.1492.




3i. 5-cyclopropyl-2-phenylpyrazolo[5,1-a]isoquinoline.

Yield: 90%; ^1H NMR (400 MHz, CDCl_3) δ : 0.94-0.96 (m, 2H), 1.18-1.21 (m, 2H), 2.83-2.88 (m, 1H), 6.55 (s, 1H), 7.31 (s, 1H), 7.34-7.37 (m, 1H), 7.44-7.48 (m, 4H), 7.57-7.59 (m, 1H), 8.04-8.07 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 7.78, 11.3, 94.9, 106.1, 123.3, 123.5, 126.5, 126.6, 126.7, 127.8, 128.3, 128.8, 129.4, 133.8, 140.2, 141.4, 152.3; HRMS calcd. for $\text{C}_{20}\text{H}_{16}\text{N}_2^+$ $[\text{M}+\text{H}]^+$: 285.1392, found 285.1390.




3j. 5-cyclopropyl-2-(4-methoxyphenyl)pyrazolo[5,1-a]isoquinoline.

Yield: 78%; ^1H NMR (400 MHz, CDCl_3): 0.94-0.97 (m, 2H), 1.21-1.25 (m, 2H), 2.85-2.88 (m, 1H), 3.86 (s, 3H), 6.56 (s, 1H), 6.99-7.01 (d, $J=8.68$ Hz, 1H), 7.26 (s, 1H), 7.46-7.48 (m, 2H), 7.57-7.61 (m, 1H), 7.98-8.00 (d, $J=8.72$ Hz, 2H), 8.06-8.08 (d, $J=6.8$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 7.63, 11.1, 55.3, 94.2, 105.5, 114.1, 123.0, 123.4, 126.3, 126.4, 127.6, 127.7, 129.3, 140.1, 141.3, 152.1, 159.7; HRMS calcd. for $\text{C}_{21}\text{H}_{18}\text{N}_2\text{O}^+$ $[\text{M}+\text{H}]^+$: 315.1497, found 315.1491.




3k. 9-fluoro-2-(4-methoxyphenyl)-5-phenylpyrazolo[5,1-a]isoquinoline.

Yield: 62%; ^1H NMR (400 MHz, CDCl_3): 3.83 (s, 3H), 6.94-6.98 (m, 3H), 7.23-7.26 (m, 2H), 7.47-7.54 (m, 3H), 7.65-7.74 (m, 2H), 7.89 (d, $J=8.68\text{Hz}$, 2H), 7.98-8.01 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 55.3, 94.7, 108.7(d, $^2J_{CF} = 22.9$ Hz), 111.4, 114.0, 116.6(d, $^2J_{CF} = 23.8$ Hz), 119.1, 125.0, 125.9, 127.6, 128.1, 129.2, 129.3, 129.6, 133.6, 137.7, 139.9, 152.1, 159.8, 161.5 (d, $^1J_{CF} = 246.0$ Hz) ; HRMS calcd. for $\text{C}_{24}\text{H}_{17}\text{FN}_2\text{O}^+$ $[\text{M}+\text{H}]^+$: 369.1403, found 369.1406.




3l. 9-fluoro-2,5-bis(4-methoxyphenyl)pyrazolo[5,1-a]isoquinoline.

Yield: 67%; ^1H NMR (400 MHz, CDCl_3): 3.85 (s, 3H), 3.90 (s, 3H), 6.94-6.97 (m, 3H), 7.04-7.06 (d, $J = 8.3$ Hz, 2H), 7.23-7.25 (m, 2H), 7.65-7.73 (m, 2H), 7.90-7.97 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 55.4, 55.5, 94.8, 108.8 (d, $^2J_{CF} = 22.9$ Hz), 110.8, 113.7, 114.1, 116.7(d, $^2J_{CF} = 23.8$ Hz), 124.9, 126.0, 126.1, 127.7, 129.3, 131.1, 137.5, 140.1, 152.1, 159.9, 160.4, 161.5 (d, $^1J_{CF} = 246.0$ Hz) ; HRMS calcd. for $\text{C}_{25}\text{H}_{19}\text{FN}_2\text{O}_2^+$ $[\text{M}+\text{H}]^+$: 399.1509, found 399.1522.




3m. 7,8,9-trimethoxy-2-(4-methoxyphenyl)-5-phenylpyrazolo[5,1-a]isoquinoline

Yield: 83%; ^1H NMR (400 MHz, CDCl_3): 3.84 (s, 3H), 3.99 (s, 3H), 4.04 (s, 3H), 4.05 (s, 3H), 6.94 (s, 1H), 6.97 (s, 1H), 7.20 (s, 1H), 7.27-7.31 (m, 2H), 7.48-7.56 (m, 3H), 7.91-7.94 (d, $J = 8.8$ Hz, 2H), 8.04-8.06 (d, $J = 6.8$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 55.4, 56.3, 61.3, 61.7, 93.7, 100.2, 106.5, 114.1, 118.9, 120.6, 126.3, 127.7, 128.2, 129.0, 129.8, 134.3, 136.6, 140.3, 142.1, 149.0, 152.0, 153.9, 159.8; HRMS calcd. for $\text{C}_{27}\text{H}_{24}\text{N}_2\text{O}_4^+$ $[\text{M}+\text{H}]^+$: 441.1814, found 441.1809.



3n. 5-butyl-9-fluoro-2-phenylpyrazolo[5,1-a]isoquinoline.


Yield: 88%; ^1H NMR (400 MHz, CDCl_3): 1.02 (t, $J = 7.3$ Hz, 3H), 1.49-1.59 (m, 2H), 1.85-1.93 (m, 2H), 3.18 (t, $J = 7.3$ Hz, 2H), 6.74 (s, 1H), 7.20-7.23 (m, 2H), 7.35-7.38 (m, 1H), 7.45-7.48 (m, 2H), 7.57-7.61 (m, 1H), 7.68 (dd, $J_1 = 0.7$ Hz, $J_2 = 2.4$ Hz, 1H), 8.02 (s, 1H), 8.03 (d, $J = 1.4$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.9, 22.5, 28.9, 30.4, 95.0, 108.5 (d, $^2J_{\text{CF}} = 21.9$ Hz), 108.6, 116.3 (d, $^2J_{\text{CF}} = 22.9$ Hz), 124.5, 125.7, 126.3, 128.2, 128.6, 128.7, 133.4, 138.9, 139.3, 152.0, 161.1 (d, $^1J_{\text{CF}} = 245.0$ Hz); HRMS calcd. for $\text{C}_{21}\text{H}_{19}\text{FN}_2^+$ $[\text{M}+\text{H}]^+$: 319.1611, found 319.1611.



3o. 5-butyl-9-fluoro-2-(4-methoxyphenyl)pyrazolo[5,1-a]isoquinoline.

Yield: 64%; ^1H NMR (400 MHz, CDCl_3): 1.02 (t, $J = 7.3$ Hz, 3H), 1.48-1.58 (m, 2H),


1.84-1.94 (m, 2H), 3.19 (t, $J = 7.3$ Hz, 2H), 3.86 (s, 3H), 6.74 (s, 1H), 6.97-7.01 (m, 2H), 7.16 (s, 1H), 7.21-7.25 (m, 1H), 7.59-7.62 (m, 1H), 7.68 (dd, $J_1 = 0.69$ Hz, $J_2 = 2.4$ Hz, 1H), 7.94-7.97 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.1, 22.7, 29.0, 30.6, 55.4, 94.6, 108.4, 108.6(d, $^2J_{\text{CF}} = 22.9$ Hz), 116.3(d, $^2J_{\text{CF}} = 23.8$ Hz), 124.5, 125.7, 126.3, 127.7, 128.6, 139.0, 139.4, 152.0, 159.8, 161.1 (d, $^1J_{\text{CF}} = 245.0$ Hz) ; HRMS calcd. for $\text{C}_{22}\text{H}_{21}\text{FN}_2\text{O}^+ [\text{M}+\text{H}]^+$: 349.1716, found 349.1721.




3p. 5-cyclopropyl-9-fluoro-2-(4-methoxyphenyl)pyrazolo[5,1-a]isoquinoline.

Yield: 62%; ^1H NMR (400 MHz, CDCl_3): 0.93-0.95 (m, 2H), 1.18-1.22 (m, 2H), 2.80-2.84 (m, 1H), 3.86 (s, 3H), 6.53 (s, 1H), 6.97-7.01 (m, 2H), 7.19-7.22 (m, 2H), 7.54-7.58 (m, 1H), 7.68 (dd, $J_1 = 0.69$ Hz, $J_2 = 2.4$ Hz, 1H), 7.96-7.98 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 7.52, 11.0, 55.3, 94.7, 105.0, 108.5(d, $^2J_{\text{CF}} = 21.9$ Hz), 114.1, 116.3(d, $^2J_{\text{CF}} = 22.9$ Hz), 124.1, 125.8, 126.2, 127.6, 128.6, 139.3, 140.5, 152.1, 161.0 (d, $^1J_{\text{CF}} = 242.2$ Hz) ; HRMS calcd. for $\text{C}_{21}\text{H}_{17}\text{FN}_2\text{O}^+ [\text{M}+\text{H}]^+$: 333.1403, found 333.1402.


3a




3a




3b




3b




3c




3c




3d




3d




3e




3e




3f




3f




3g




3g




3h




3h




3i




3i




3j




3j




3k




3k




31




31




3m




3m




3n




3n



30





3p

